News
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024 Vigil Neuroscience, Inc. Wed, Mar 6, 2024, 4:25 PM 4 min read ...
Data selected for oral presentation reinforce previous findings on safety and efficacyMALVERN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company ...
Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLDSymposium™ 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback